Total Number of Patients                                   102 (100%)

Patients with Bacterial Infections                        37 (36.3%)

Males : Females                                                   50 (49%) : 52 (51%)

Mean Age (SD) years                                          72.3 (11.1) : 73.1 (13.2)

Range Age years  M:F                                         (42.8-89.6 : 31.6-96.2)

Admission Diagnosis Malignant                         94 (92.2%)

Admission Diagnosis Non Malignant                   8 (7.8%)

Median overall patient survival (IQR)^*               12 (4-29) days

Median patient survival with infections              22 (6-39) days

Patient survival < 7 days                                      40 (39.2%)

Patient survival 7-14 days                                    15 (14.7%)

Patient survival >14 days                                     47 (46.1%)

Diagnosis                                             n            %                   95%CI

Digestive tract cancer

28

27.5%

19.1-37.2%

Lung cancer

20

19.6%

12.4-28.6%

Genitourinary cancer

16

15.7%

9.2-24.2%

Haematological malignancies

7

6.8%

2.8-13.6%

Skin cancer

6

5.9%

2.2-12.4%

1°Brain cancer

5

4.9%

1.6-11.1%

Carcinoma unknown primary site

5

4.9%

1.6-11.1%

Breast cancer

4

3.9%

1.1-9.70%

Mesothelioma pleura

3

2.9%

0.6-8.40%

Non Malignant Disease

8

7.8%

3.5-14.9%

Total:

102

100%

Site of Infection

(n)

Antibiotic

Used

Prescrib

Times

(n)

Culture

Or

Empiric^*

Route

Symptom Response

Yes/No

Urinary Tract (17)

First Line

Second Line

Trimethoprim

Cephalexin

Augmentin Forte

Dicloxacillin

Cotrimoxazole

Gentamicin

9

4

2

1

1

1

C(7)E(2)

C(3)E(1)

C(2)

      C(1)

C(1)

     C(1)

PO

PO

PO

    PO

PO

PO

Yes(4)

Yes(2)

Yes(2)

       No(1)

No(1)

Yes(1)

Respiratory Tract (9)

First Line

Second Line

Augmentin Forte

Ciprofloxacin

Trimethoprim

Cotrimoxazole

Isoniazid

Augmentin Forte

2

2

3

1

1

1

C(1)E(1)

C(1)E(1)

C(2)E(1)

C(1)

E(1)

C(1)

PO

PO

PO

PO

PO

PO

Yes(1)No(1)

No(2)

Yes(2)No(1)

No(1)

No(1)

No(1)

Blood/Bacteremia (5)

First Line

Second Line

Ampicillin

Gentamicin

Augmentin Forte

Ciprofloxacin

Penicillin V

Switched to

Ampicillin

Amoxycillin

Ceftriaxone

1

1

1

1

1

1

1

1

C(1)

C(1)

C(1)

C(1)

C(1)

C(1)

C(1)

C(1)

IV

IV

PO

PO

PO

IV

PO

IV

Yes(1)

No(1)

No(1)

No(1)

No(1)

No(1)

Yes(1)

No(1)

Skin/Subcutaneous (5)

Amoxycillin

Cephalexin

Cotrimoxazole

Metronidazole

Trimethoprim

1

1

1

1

1

C(1)

C(1)

C(1)

C(1)

C(1)

PO

PO

PO

PO

PO

Yes(1)

No(1)

No(1)

No(1)

No(1)

Eyes (4)

Chloramphenicol

Ointment 0.5%

4

E(4)

Tp

Yes(4)

Organism / Site

n

Antibiotic Sensitivities % (n)

Amox Amp AugF Cep Cef  Cip Gen Cot/Tri  Van Pen Ery Tic Met  Clox

Escherichia coli

- urinary tract(5)^*

- blood (2)

7

  66.7  100    100   100 100    -   100     100     100 100   -       -    -        -

 (4/6)  (1/1)  (1/1) (5/5)(1/1)      (7/7)    (7/7)   (2/2)(2/2)

Enterobacter fecalis

 - urinary tract (3)

3

  66.7      -     50     75  100    -    100     100        -    0.0    -   100  -        -

 (2/3)           (1/2) (3/4)(1/1)       (4/4)   (5/5)            (0/2)      (1/1)

Staphylococcus aureus

- urinary tract (1)

- skin (1)

2

   -          -     100   100 100    -    100       -           -    0.0 100 100 100    -

                    (1/1) (2/2)(1/1)        (1/1)                    (0/2)(2/2)(1/1)(1/1)

Pseudomonas aeruginosa

- urinary tract

2

 100       -        -       -    100   -     100    100         -    0.0 100100   -    100

(1/1)                            (1/1)        (2/2)  (1/1)            (0/1)(1/1)(2/2)    (1/1)

Strepcoccus bovis

- blood

1

    -         -        -       -      -      -       -         -        100  100   -      -    -      -

Enterobacter aerogenes

 - urinary tract (1)*

 - skin (1)

2

  0.0       -       0.0   0.0    -      -     100    100        -       -     -      -    -      -

 (0/2)             (0/2) (0/2)              (2/2)   (4/4)        

Enterococcus species

- skin

1

   -          -            -     -    -       -       -         -        0.0     -     -     -     -      -

                                                                           (0/1)

Streptococcus pyogenes group A

- blood

   1

 100       -            -      -   -       -     100       -       100   100  -     -     -      -

Proteus mirabilis

- urinary tract*

1

   -       100       100  100  -   100    100    100        -       -        -     100     -       -

Total:

20

Variable

Patients with infection

Yes (n)                No (n)

Mann-Whitney

U test²⁵

Total Patients in groups

Median Survival (days)

35                             67

22                             10

P = .013

Mean(SD) Char Score

Mean(SD) Ajd Char Score

6.9 (3)                      6.5 (3.4)

5.0 (2.9)                   4.6 (3.3)

ns

ns

Prominent Symptoms

-           severe pain

-           dyspnea

-           immobility

-           depression/anxiety

-           confusion

-           weakness

-           loss appetite

-           nausea/vomiting

6 (17.1%)                 13 (19.4%)

5 (14.3%)                 19 (28.4%)

28 (80.0%)                55 (82.1%)

8 (22.9%)                 14 (40.0%)

10 (28.6%)                32 (47.8%)

24 (68.6%)                38 (56.7%)

19 (54.3%)                24 (35.8%)

13 (37.1%)                14 (21.0%)

ns

ns

ns

ns

ns

ns

ns

ns

Primary Carer

23 (65.7%)                43 (64.2%)

ns

Family Support

24 (68.6%)                33 (49.3%)

ns

Comfortable Death

30 (85.7%)                35 (52.2%)

ns

Family Conflict

6 (17.1%)                   4 (6.00%)

ns

Major Psychological distress post admission

20 (57.1%)                  6 (8.90%)

P = .001

Major Depression

post admission

6 (17.1%)                   5 (7.50%)

ns